MannKind (MNKD) Receives a Grant from Breakthrough T1D

MannKind Corporation (NASDAQ:MNKD) is one of the Best Rising Penny Stocks to Buy According to Wall Street Analysts. Recently, on June 23, MannKind Corporation (NASDAQ:MNKD) announced receiving a grant from Breakthrough T1D, which is a leading type 1 diabetes research organization.

​The grant is to support the INHALE-1ST clinical trial evaluating inhaled insulin in newly diagnosed pediatric patients. The stock has gained more than 4% since the release and around 13% over the past month.

​Management noted that the trial in question focuses on Afrezza, the company’s inhaled insulin product, used alongside a daily injectable basal insulin in patients aged 10 to 17 who have recently been diagnosed with type 1 diabetes. The study aims to assess both safety and efficacy in this younger population.

​The grant reflects external validation of Afrezza’s potential and builds on a recent FDA approval allowing Afrezza’s use in children as young as six. The insulin works by delivering insulin through the lungs at mealtime using the company’s Technosphere platform, enabling rapid absorption that closely mimics the body’s natural insulin response. Management noted that if the new product is successful, it can open a new market for the company.

MannKind Corporation (NASDAQ:MNKD) is a biopharmaceutical company that specializes in chronic disease care. Incorporated in 1991, the company provides solutions for serious conditions, such as diabetes, pulmonary hypertension, and fluid overload.

READ NEXT: Top 10 Large-Cap Stocks to Invest In At 52-Week Lows and 12 High Growth Semiconductor Stocks to Buy Now. 

Disclosure: None. Follow Insider Monkey on Google News.